: Cancer treatment company Adlai Nortye sets terms in IPO


Adlai Nortye Ltd. said late Thursday it plans to offer three million American depositary shares at an estimated price of $22 to $26 a share in its initial public offering on the Nasdaq under the symbol “ANL”. The Cayman Islands-based clinical-stage cancer treatment company with operations in the U.S. and China will raise about $72 million at the midpoint of its estimated price range with underwriter Cantor Fitzgerald and CLSA. Japanese chemical company Nippon Kayaku Co. Ltd. has agreed to buy $40 million in Class A ordinary shares from Adlai Nortye in a private placement.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: UBS cuts the cord, severing backstop Swiss government provided to buy Credit Suisse
Next articleU.K. economy expands 0.2% in second quarter of 2023, more than forecast


Please enter your comment!
Please enter your name here